• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cannabis Stock Movers For July 1, 2024

    7/1/24 4:30:05 PM ET
    $CARA
    $CRBP
    $EAST
    $GNLN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CARA alert in real time by email

    GAINERS:

    • Affinor Growers (OTC:RSSFF) shares closed up 76.74% at $0.17
    • Global Compliance (OTC:FUAPF) shares closed up 39.00% at $0.01
    • CNBX Pharmaceuticals (OTC:CNBX) shares closed up 33.33% at $0.01
    • Elixinol Wellness (OTC:ELLXF) shares closed up 32.50% at $0.00
    • SOL Glb Inv (OTC:SOLCF) shares closed up 18.50% at $0.05
    • Target Group (OTC:CBDY) shares closed up 10.90% at $0.00
    • Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 9.17% at $49.40
    • Auxly Cannabis Group (OTC:CBWTF) shares closed up 7.14% at $0.02
    • Cara Therapeutics (NASDAQ:CARA) shares closed up 7.02% at $0.26
    • Cannabix Technologies (OTC:BLOZF) shares closed up 4.24% at $0.35
    • Cansortium (OTC:CNTMF) shares closed up 3.85% at $0.14
    • CLS Holdings USA (OTC:CLSH) shares closed up 3.53% at $0.04

    LOSERS:

    • Global Hemp Group (OTC:GBHPF) shares closed down 39.05% at $0.02
    • CordovaCann (OTC:LVRLF) shares closed down 33.73% at $0.04
    • MJ Holdings (OTC:MJNE) shares closed down 33.03% at $0.00
    • 1933 Industries (OTC:TGIFF) shares closed down 32.00% at $0.01
    • 4Front Ventures (OTC:FFNTF) shares closed down 26.74% at $0.06
    • Pharmadrug (OTC:LMLLF) shares closed down 12.62% at $0.01
    • CV Sciences (OTC:CVSI) shares closed down 11.37% at $0.05
    • 22nd Century Group (NASDAQ:XXII) shares closed down 8.76% at $0.70
    • Greenlane Hldgs (NASDAQ:GNLN) shares closed down 7.94% at $0.30
    • C21 Investments (OTC:CXXIF) shares closed down 7.69% at $0.25
    • Rocky Mountain High (OTC:RMHB) shares closed down 7.69% at $0.01
    • Leafbuyer Techs (OTC:LBUY) shares closed down 7.00% at $0.02
    • Charlottes Web Holdings (OTC:CWBHF) shares closed down 5.26% at $0.18
    • Blueberries Medical (OTC:BBRRF) shares closed down 4.08% at $0.01
    • Eastside Distilling (NASDAQ:EAST) shares closed down 3.84% at $0.97
    • Urban-gro (NASDAQ:UGRO) shares closed down 3.76% at $1.33
    • Body and Mind (OTC:BMMJ) shares closed down 3.52% at $0.04
    • RIV Capital (OTC:CNPOF) shares closed down 3.06% at $0.10

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CARA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CARA
    $CRBP
    $EAST
    $GNLN

    CompanyDatePrice TargetRatingAnalyst
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2025$28.00Buy
    B. Riley Securities
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    2/28/2025Outperform
    William Blair
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    12/2/2024Overweight
    Piper Sandler
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2024$85.00Outperform
    Wedbush
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/22/2024$80.00Buy
    H.C. Wainwright
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    6/26/2024$85.00Buy
    B. Riley Securities
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$6.00 → $1.00Buy → Hold
    Stifel
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$10.00 → $1.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $CARA
    $CRBP
    $EAST
    $GNLN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $EAST
    $GNLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities resumed coverage on Corbus Pharma with a new price target

    B. Riley Securities resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $28.00

    7/30/25 8:22:15 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Corbus Pharma

    William Blair initiated coverage of Corbus Pharma with a rating of Outperform

    2/28/25 7:22:12 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Corbus Pharma

    Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight

    12/2/24 9:55:40 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $EAST
    $GNLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    Greenlane Highlights Berachain Addition of Ethena USDe as Approved Collateral for HONEY Stablecoin

    USDe approved as collateral to mint Berachain's HONEY stablecoin Expands HONEY collateral set alongside USDT0, USDC, and PayPal USD (pyUSD) BOCA RATON, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN), a company pursuing a Berachain-focused digital asset treasury strategy, today highlighted Berachain's integration of Ethena's USDe as approved collateral for HONEY, Berachain's native stablecoin. The integration is intended to expand the range of dollar-based collateral available on Berachain and may support protocol-level liquidity, network activity, and on-chain economic mechanisms within the Berachain ecosystem.¹,² HONEY is B

    1/29/26 7:00:00 AM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    Digital Asset Treasury Strategy Positions Companies for Long-Term Shareholder Value

    Strategic allocation aims to hedge inflation risk while aligning with the future of digital finance NEW YORK  , Jan. 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - More companies are starting to rethink how they manage their balance sheets, and digital asset treasury strategies are quickly moving into the spotlight. Instead of letting excess cash sit idle and lose purchasing power, some organizations are allocating a portion of their treasury into digital assets like Bitcoin and other blockchain-based instruments. For investors, this isn't about chasing hype — it's about companies taking a more active, modern approach to protecting and growing capital in a world where inflati

    1/20/26 8:45:00 AM ET
    $BMNR
    $CIFR
    $COIN
    Finance: Consumer Services
    Finance
    Durable Goods
    Consumer Discretionary

    $CARA
    $CRBP
    $EAST
    $GNLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Ip Jonathan Hue-Fay

    3 - Greenlane Holdings, Inc. (0001743745) (Issuer)

    2/4/26 4:55:45 PM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    Chief Medical Officer Smethurst Dominic sold $26,575 worth of shares (3,285 units at $8.09), decreasing direct ownership by 3% to 95,887 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/4/26 4:25:42 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Hodgson Ian sold $19,537 worth of shares (2,415 units at $8.09), decreasing direct ownership by 4% to 51,927 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/4/26 4:24:39 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $EAST
    $GNLN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO of Subsidiary Liuzza Nicholas Reyland Jr bought $36,749 worth of shares (45,000 units at $0.82) (SEC Form 4)

    4 - Eastside Distilling, Inc. (0001534708) (Issuer)

    12/11/24 5:18:50 PM ET
    $EAST
    Beverages (Production/Distribution)
    Consumer Staples

    Large owner Cormorant Asset Management, Lp bought $7,003,761 worth of shares (350,000 units at $20.01) (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    9/24/24 4:04:18 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    9/12/24 5:00:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CRBP
    $EAST
    $GNLN
    SEC Filings

    View All

    SEC Form 10-Q filed by urban-gro Inc.

    10-Q - urban-gro, Inc. (0001706524) (Filer)

    2/10/26 3:34:03 PM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SCHEDULE 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    2/10/26 1:14:49 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    urban-gro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - urban-gro, Inc. (0001706524) (Filer)

    2/9/26 7:37:26 PM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    $CARA
    $CRBP
    $EAST
    $GNLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $EAST
    $GNLN
    Financials

    Live finance-specific insights

    View All

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

    CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host conference call and live webcast today at 8:00 am ET NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending d

    12/11/25 7:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

    NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced the Company's plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursday, December 11, 2025. Corbus will host a conference call and live webcast the same day at 8:00 am ET to review and discuss the Phase 1a data. To register for the webcast, click here . A replay will be available on the Corbus website. About CRB-913CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (

    12/10/25 4:01:00 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $EAST
    $GNLN
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at urban-gro Inc. on Jun 6

    Urban-gro Inc. saw an interesting insider purchase on June 6, 2024, when Wilks Lewis bought $29,000 worth of shares, acquiring 20,000 units at a price of $1.45 per unit. This transaction increased Lewis' direct ownership by 12% to 184,108 units, as reported in SEC Form 4. Insider transactions like this can provide valuable insights for investors, indicating confidence in the company's future prospects. Analyzing the insider activity surrounding Urban-gro Inc., we can observe several transactions that may reveal patterns or insights. Looking back at previous filings, on September 1, 2023, Wilks Lewis purchased $10,300 worth of shares, acquiring 10,000 units at $1.03 per unit. This

    6/10/24 12:49:49 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    $CARA
    $CRBP
    $EAST
    $GNLN
    Leadership Updates

    Live Leadership Updates

    View All

    22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 States

    Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a

    8/4/25 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    3WIN Corp. Appoints Craig Snyder as Chief Executive Officer and Director

    TEMPE, Ariz., April 22, 2025 (GLOBE NEWSWIRE) -- 3WIN Corp. ("3Win" or the "Company"), a Tempe, Arizona-based global wholesale distributor of CCELL® vape products, is pleased to announce the appointment of Craig Snyder as Chief Executive Officer ("CEO") and member of the Board of Directors, effective April 17, 2025. Mr. Snyder was previously hired as Chief Transformation Officer in early March of 2025. Relatedly, Christopher J. Sinacori has been appointed Executive Chairman of the Board and has assumed the role of President from previously being CEO. Jeffrey A. Sinacori has transitioned to Chief Operating Officer from previously being President, while remaining on the Board as a Director.

    4/22/25 9:10:12 PM ET
    $GNLN
    Durable Goods
    Consumer Discretionary